| Code | CSB-RA847747MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to SAR444881, designed to target LILRB1 (Leukocyte Immunoglobulin-Like Receptor B1), also known as ILT2 or CD85j. LILRB1 is an inhibitory receptor expressed on myeloid cells and certain lymphocyte subsets that binds to classical and non-classical MHC class I molecules. Upon engagement, LILRB1 delivers immunosuppressive signals through its ITIM domains, dampening immune cell activation and cytotoxic responses. This receptor plays a critical role in maintaining immune homeostasis but is frequently exploited by tumors to evade immune surveillance. LILRB1 overexpression has been associated with various malignancies, including acute myeloid leukemia, and contributes to the immunosuppressive tumor microenvironment.
SAR444881 is a therapeutic antibody candidate developed to block LILRB1 function, thereby restoring anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating LILRB1-mediated immune regulation, exploring checkpoint inhibition mechanisms, and studying myeloid cell biology in cancer and autoimmune contexts. It supports preclinical studies examining immunotherapeutic strategies targeting the LILRB1 pathway.
There are currently no reviews for this product.